4.6 Article

Sedation, Analgesia, and Paralysis during Mechanical Ventilation of Premature Infants

Journal

JOURNAL OF PEDIATRICS
Volume 180, Issue -, Pages 99-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2016.07.001

Keywords

-

Categories

Funding

  1. Duke Clinical and Translational Science Award [KL2TR001115-03]
  2. Cempra Pharmaceuticals [HHS0100201300009C]
  3. AbbVie
  4. Astellas Pharma US
  5. GlaxoSmithKline
  6. Mission Pharma
  7. National Institutes of Health (NIH) [1R21HD080606-01a1]
  8. National Center for Advancing Translational Sciences of the NIH [UL1TR001117]
  9. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) [HHSN275201000003I]
  10. Food and Drug Administration [1R18-FD005292-01]
  11. US Government [HHSN267200700051C]
  12. NICHD [K23 HD068497]
  13. National Heart, Lung, and Blood Institute [R34 HL124038]
  14. Gerber Foundation
  15. National Institute on Aging [R01/R56 AG023178]
  16. NIH [R01 CA174453, R01 HL118255, R21-HD080214]
  17. Comparative Effectiveness Research Strategic Initiative
  18. NC TraCS Institute
  19. UNC Clinical and Translational Science Award [UL1TR001111]
  20. Center for Pharmacoepidemiology
  21. Amgen
  22. AstraZeneca

Ask authors/readers for more resources

Objective To characterize administration of sedatives, analgesics, and paralytics in a large cohort of mechanically ventilated premature infants. Study design Retrospective cohort study including all infants <1500 g birth weight and <32 weeks gestational age (GA) mechanically ventilated at 348 Pediatrix Medical Group neonatal intensive care units from 1997 to 2012. The primary outcome is the proportion of mechanically ventilated days in which infants were administered drugs of interest. Multivariable logistic regression was used to evaluate the predictors of administration of drugs of interest. Results We identified 85 911 mechanically ventilated infants. Infants received a drug of interest (opioids, benzodiazepines, other sedatives, and paralytics) on 433 587/1 305 413 (33%) of mechanically ventilated infant days. The administration of opioids increased during the study period from 5% of infant days in 1997 to 32% in 2012. The administration of benzodiazepines increased during the study period from 5% of infant days in 1997 to 24% in 2012. Use of paralytics and other drugs remained <= 1% throughout the study period. Predictors of drug administration included younger GA, small for GA status, male sex, presence of a major congenital anomaly, older postnatal age at intubation, exposure to high-frequency ventilation, exposure to inotropes, more recent year of discharge, and neonatal intensive care unit site. Conclusions Administration of opioids and benzodiazepines in mechanically ventilated premature infants increased over time. Because infant characteristics were unchanged, site-specific differences in practice likely explain our observations. Increased administration over time is concerning given limited evidence of benefit and potential for harm.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available